Surging interest in cancer bioenergetics has brought drug developers into the fray, but the field awaits a clinical success. Ken Garber explores the extent to which the concept is entering the mainstream.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Garber, K. Nat. Biotechnol. 28, 763–764 (2010).
Yun, J. et al. Science 325, 1555–1559 (2009).
Zhao, S. et al. Science 324, 261–265 (2009).
Dang, L. et al. Nature 462, 739–744 (2009).
Christofk, H. et al. Nature 452, 181–186 (2008).
Christofk, H. et al. Nature 452, 230–233 (2008).
DeBerardinis, R.J. et al. Proc. Natl. Acad. Sci. USA 104, 19345–19350 (2007).
Gao, P. et al. Nature 458, 762–765 (2009).
Choo, A. et al. Mol. Cell 38, 487–499 (2010).
Le, A. et al. Proc. Natl. Acad. Sci. USA 107, 2037–2042 (2010).
Michelakis, E.D. et al. Sci. Transl. Med. 2, 31ra34, 1–8 (2010)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Oncology's energetic pipeline. Nat Biotechnol 28, 888–891 (2010). https://doi.org/10.1038/nbt0910-888
Issue Date:
DOI: https://doi.org/10.1038/nbt0910-888
This article is cited by
-
First metabolic oncology inhibitor gets FDA green light, with record price tag
Nature Biotechnology (2017)
-
Structural Basis for the Active Site Inhibition Mechanism of Human Kidney-Type Glutaminase (KGA)
Scientific Reports (2014)
-
PDK1 inhibition is a novel therapeutic target in multiple myeloma
British Journal of Cancer (2013)
